1-甲基-3,5-哌啶二醇 | 408330-34-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-甲基-3,5-哌啶二醇
• 中文别名: 1-甲基哌啶-3,5-二醇
• 英文名称: 1-methyl-piperidine-3,5-diol
• 英文别名: 1-Methyl-piperidin-3,5-diol；1-methylpiperidine-3,5-diol
• CAS: 408330-34-7
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: ZCXSVFOPYLLQLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  1,4-戊二烯 在 次氯酸叔丁酯 、 溶剂黄146 作用下， 生成 1-甲基-3,5-哌啶二醇
  参考文献：
  名称：

  Paul; Tchelitcheff, Bulletin de la Societe Chimique de France, 1948, p. 896,900

  摘要：

  DOI：

文献信息

• QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR
  申请人：Abbvie Deutschland GmbH & Co. KG

  公开号：US20170260158A1

  公开（公告）日：2017-09-14

  The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT 6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT 6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT 6 receptor.

  本发明涉及公式I的喹啉化合物，其中变量的定义如索引和描述中所述。本发明还涉及含有这种化合物的药物组合物，以及它们作为5-HT6受体调节剂的用途，用于制备用于预防或治疗对5-HT6受体调节有反应的疾病和疾病的药物，以及用于预防或治疗对5-HT6受体调节有反应的疾病和疾病的方法。
• 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS
  申请人：Miyaji Katsuaki

  公开号：US20090281317A1

  公开（公告）日：2009-11-12

  A compound represented by the formula (1): wherein A, B, R 1 , L 1 , R 2 , L 2 , L 3 , Y, L 4 , R 3 and X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

  一种由式（1）所表示的化合物：其中A、B、R1、L1、R2、L2、L3、Y、L4、R3和X的定义与说明中相同，该化合物的互变异构体、前药或药学上可接受的盐或其溶剂。
• Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
  申请人：FUCHINO Kouki

  公开号：US20100216726A1

  公开（公告）日：2010-08-26

  The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

  本发明涉及取代喹喔啉型哌啶化合物、包含有效量取代喹喔啉型哌啶化合物的组合物以及治疗或预防某种疾病（如疼痛）的方法，包括向需要治疗的动物施用有效量取代喹喔啉型哌啶化合物。
• SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20150141643A1

  公开（公告）日：2015-05-21

  The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

  该发明涉及取代喹喔啉型哌啶化合物，包括一种有效量的取代喹喔啉型哌啶化合物的组合物以及治疗或预防疾病的方法，例如疼痛，通过向需要治疗的动物施用一种有效量的取代喹喔啉型哌啶化合物。
• TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20160122336A1

  公开（公告）日：2016-05-05

  The present invention comprises compounds of Formula I. wherein: X, A 1 , A 2 , A 3 , A 4 , R 1 , R 2 , and R 3 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涉及I式化合物，其中：X，A1，A2，A3，A4，R1，R2和R3在说明书中有定义。本发明还涉及一种治疗或改善综合症、障碍或疾病的方法，其中所述的综合症、障碍或疾病是类风湿性关节炎或银屑病。本发明还涉及一种通过给哺乳动物投予至少一种权利要求1中的化合物的治疗有效量来调节RORγt活性的方法。